medigraphic.com

2019, Number 3

Next >>

Rev Hematol Mex 2019; 20 (3)

Towards a new age in the treatment of acute myeloblastic leukemia

Best-Aguilera CR, Rivera-Mendoza LA, Acosta-Hernández TC, Guzmán-Hernández AE

Language: Spanish
References: 28
Page: 185-188
PDF size: 229.45 Kb.


Text Extraction

No abstract.


REFERENCES

  1. Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, et al. Long-term outcome of acute promyelocytic leukemia treated with all- trans -retinoic acid, arsenic trioxide, and gemtuzumab. Blood 2017;129(10):1275-83.

  2. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood 2006;107(9):3481-85.

  3. Goldstone AH, Burnett AK, Wheatley K, et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 2001;98:1302-1311.

  4. Krug U, Röllig C, Koschmieder A, Heinecke A, et al. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet 2010;376:2000-08.

  5. Mantovani L, Hasenclever D, Krahl R, Pönisch W, Herold M, Pasold R, et al. Intermediate-dose cytarabine treatment delivered at moderate infusion rates for de novo acute myeloid leukemia-results of a phase I-II study. Leuk Lymphoma 2002 Jan;43(2):265-74.

  6. Wu D, Duan C, Chen L, Chen S. Efficacy and safety of different doses of cytarabine in consolidation therapy for adult acute myeloid leukemia patients: a network meta-analysis. Sci Rep 2017;7(1).

  7. Thomas X, Elhamri M, Raffoux E, et al. Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: theALFA-9802 study. Blood 2011;118,(7):1754-62.

  8. Schaich M, Rollig C, Soucek S, et al. Cytarabine dose of 36 g/m2 compared With 12 g/m2 within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study. J Clin Oncol 2011;29(19):2696-2702.

  9. Gary Gilliland D, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002;100(number 5):1532-42. doi:10.1182/blood-2002-02-0492.

  10. Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K, et al. Internal tandem duplication of the FLT3 gene found in acute myeloid leukemia. Leukemia 1996;10:1911-8.

  11. Levis M. Midostaurin approved for FLT3-mutated AML. Blood 2017;129(26):3403-3406.

  12. Ostronoff F, Estey E. The role of quizartinib in the treatment of acute myeloid leukemia. Expert Opin Invest Drugs 2013;22(12):1659-1669.

  13. Stone RM, Dohner H, Ehninger G, Villeneuve M, Teasdale T, Virkus JD, et al. CALGB 10603 (RATIFY): A randomized phase III study of induction (daunorubicin/cytarabine) and consolidation (high-dose cytarabine) chemotherapy combined with midostaurin or placebo in treatment-naive patients with FLT3 mutated AML. J Clin Oncol 2011 May 20;29(15 suppl):TPS199-TPS199.

  14. Grunwald MR, Levis MJ. FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance. Int J Hematol 2013 Jun;97(6):683-94.

  15. Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, Letai, A. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discovery 2016;6(10):1106-1117.

  16. www.fda.gov/drugs/fda-approves-venetoclax-combination- aml-adults.

  17. DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatmentnaive, elderly patients with acute myeloid leukemia. Blood 2019;133(1):7-17.

  18. DiNardo CD, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med 2018. https://doi.org/10.1056/NEJMoa1716984.

  19. Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia. Blood 2017;130(6):722-31.

  20. Burnett A, Cavenagh J, Russell N, et al. Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 Trial. Haematologica 2016;101(6):724-731.

  21. Thomas ED, Lochte Jr HL, Lu WC, Ferrebee JW. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med 1957;257:491-6.

  22. Brunner AM, et al. Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. Br J Haematol 2016.

  23. ASH 2018 | Maintenance therapy with sorafenib in patients with FLT3-ITD acute myeloid leukemia –SORMAIN trial. Burchert A, et al. Sorafenib as maintenance therapy post allogeneic stem cell transplantation for FLT3-ITD positive AML: results from the randomized, double-blind, placebo-controlled multicentre Sormain Trial 2018 Dec 3; Oral.

  24. Grace Xiuqing Lia, Lan Wangb, Bassam Yaghmour, et al. The role of FLT3 inhibitors as maintenance therapy following hematopoietic stem cell transplant. Leuk Res Rep 2018;10:26-36.

  25. Schlenk R, Döhner K, Salih H, et al. Midostaurin in combination with intensive induction and as single agent maintenance therapy after consolidation therapy with allogeneic hematopoietic stem cell transplantation or high-dose cytarabine (NCT01477606). Blood 2015;126:322.

  26. Dhillon S. Gilteritinib: First Global Approval. Drugs 2019.

  27. www. clinical trials register. eu/ctr-search/ search?query=2016-001061-83

  28. https://clinicaltrials.gov/ct2/show/NCT03564821




2020     |     www.medigraphic.com